research Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
Search
for
Sort by
Research
120-150 / 1000+ resultsresearch Doxetaxel: new indication. Prostate cancer: a few more weeks.
Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
research Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta‐Analysis
Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
research Rapid hair depigmentation in patient treated with pazopanib
Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
research Case report of Esophagus Squamous Cell Carcinoma treated with Novel Drug Preparation Method of Catheranthus rosea (Periwinkle) - An Integrated Oncological approach
The patient showed tumor stability and improved health using a new Periwinkle preparation with chemotherapy.
research Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
research Anticancer activity of cepharanthine on non-small cell lung cancer cells
Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.
research Targeting telomeric RNA quadruplexes with natural metabolites to prevent cancer
research A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).
Topical calcitriol is safe for preventing hair loss during chemotherapy.
research Antitumour and toxic effects on Wistar rats of two new platinum complexes
The new platinum complexes effectively increased survival in rats with tumors, despite some reversible side effects.
research Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects
Vismodegib is effective for basal cell carcinoma but has severe side effects.
research Rivaroxaban-induced hair loss
Rivaroxaban may cause hair loss.
research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
research Anticancer Effects of Cepharanthine: an Updated Minireview
Cepharanthine shows promise as a natural anticancer treatment.
research Drug safety evaluation of exemestane
Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients
Golvatinib shows promise as a treatment for Omicron in elderly patients.
research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
research Finasteride with Doxazosin to Reduce BPH Progression
research Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
research A prospective observational study on drug safety monitoring and Pharmacoeconomics in patients with locally advanced unresectable NSCLC in a tertiary care hospital
Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.
research A distinct cutaneous reaction to sorafenib and a multikinase inhibitor
Sorafenib can cause a unique skin reaction.
research Finasteride < Rec INN; BAN; USAN >
research RASopathic Skin Eruptions during Vemurafenib Therapy
Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
research Mitoxantrone
Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
research High incidence of severe hand–foot syndrome during capecitabine–docetaxel combination chemotherapy
About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
research Targeting Solid Tumours With Potassium Channel Activators. A Return to Fundamentals?
Potassium channel activators like nicotinamide and minoxidil might help treat solid tumors.
research SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Entospletinib effectively prevents eye and skin GVHD in mice.
research Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study
The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
research Hormone Blocking Anticancer Drugs
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.